Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: LINFOMA, LINFÓCITOS T, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
O'CONNOR, Owen A et al. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma. Journal of clinical oncology, v. 37, n. 8, p. 613-+, 2019Tradução . . Disponível em: https://doi.org/10.1200/JCO.18.00899. Acesso em: 19 out. 2024.APA
O'connor, O. A., Ozcan, M., Jacobsen, E. D., Roncero, J. M., Trotman, J., Demeter, J., et al. (2019). Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma. Journal of clinical oncology, 37( 8), 613-+. doi:10.1200/JCO.18.00899NLM
O'connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma [Internet]. Journal of clinical oncology. 2019 ; 37( 8): 613-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.18.00899Vancouver
O'connor OA, Ozcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A. Randomized phase III study of alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma [Internet]. Journal of clinical oncology. 2019 ; 37( 8): 613-+.[citado 2024 out. 19 ] Available from: https://doi.org/10.1200/JCO.18.00899
